Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I saw a 11.64 paint on Yahoo
11.64 After Hours fresh post
Correct
ARNA has been such a disaster stock. There are biotechs that have gone up several bags in the last 2 years. Not ARNA bcs. belviq is not selling.
DOWNvvvvvvvvvvvvvvvvvv
ARNA will go below the support at $1 because there is a lot more shares.
Get out.
dumped all at massive loss.
ill see you guys at $1
look on the chart
gone, and deleting this board
suckage on a huge scale
no news
Finally some good news
Suckage, we should be in something else
Belviq is a great product and cheap I think but drugs in the country must be on insurance.
Or have Ellen pump it. That greedy woman would need options first which would have to be filed.
Belviq sales need to go up 50X
For whatever reason (no insurance) this drug is not selling.
Maybe the best strategy is to take losses now and buy back at like 1.5 when the shorts are covering
my last story stock
all info on internet is lies
ignore anything in english before you buy a stock
arna will prob. dilute massively again, because everyone makes like 367k per year there.
God I hate story stocks. All news is lies.
7.67 + all debt
God. All this will push it down to 50c.
New drugs. -50%.
Europe. -40%
Then more dilution. S-8
Never buy story stocks. Its all crap.
I now have more than 7000 shares, some free.
Improves general ugliness and lightens skin tone as well. Increases height in 13% patients in a recent University study.
Cramer trashed ARNA again for his hedge fund buddies. He is dirty, but rich.
Stock lies. Employee stock plans are always dilution. Let the bastards buy shares like we do. Insist.
Done. I posted the link.
They filed the S8 2 days ago. I posted the link.
ARNA is now dumping S-8 shares. S-8 is raw dilution.
Raw Dilution of Shares = S-8
S-8 45M Shares
Worthless interview. CNBC needs to cut.
But Im long groupon and a customer.
Sold all VVUS at loss.
Going to zero.
Ill put the money into ARNA.
who knows
ive got stops in place
buy ARNA calls
long 1900 shares around 6.11 glta
this pos really sucks
2000 shares right under 15 im long
ARNA is such a strong buy and I will be adding more soon.
1) Fat pill
2) Massive shorts
3) Marketing costs: unlike VVUS, ARNA has this other rich company to eat the marketing spend. They give up a lot of revenue, but its easy on the cash.
4) Low price
5) Negative attitude. Street guys like Cramer hate these stocks.
I think Q revs r up 100%
Not shabby
Sales are going up
I agree.
VVUS management are good scientists but they dont know how to run a drug company.
Bring in the new.
Nothing has changed except more time is lost. Still waiting on DEA. Europe had already denied Belviq months ago.
Arena has not closed down yet. Is that the brightness?
Utter Collapse
Arena has been unable to move up in price despite an extremely fair, detailed, and bullish analysis by KLLJ Investments. Since my comparison showing Belviq is far more marketable than Qsymia, Arena's price has not moved despite substantial movement in the S&P, Vivus, and Orexigen's (OREX). In contrast, and although Vivus' stock initially dropped, it has since risen 14%. This move appears to reflect shareholder hope that Vivus can do better now that the FDA agreed to allow Qsymia to be sold in "certified" brick-and-mortar pharmacies and due to an increase in the monthly number of prescriptions to 23,812 in March.
A CHMP recommendation for even a conditional approval would be a major event unlike any for Arena since Belviq was approved by the FDA. Belviq is not likely to sell as well on that side of the Atlantic, nor will it sell immediately, so do not expect a pop like we had with FDA approval. Since Arena shares dropped 26% after the CHMP issued Arena the LoOI, a pop of that magnitude would be a fair and conservative estimate of what we can expect with good news.
A negative CHMP assessment should have less of an impact on Arena since analysts and shareholders are less convinced than ever of a European approval. It will also be countered by DEA approval because sales matters most.
The pop associated with the issuance of a final schedule for Belviq by the DEA will be larger if Eisai is granted the waiver to immediately sell Belviq. I am not going to predict how big it will be since Arena is hunted by bears. Until we get data on prescriptions, the bears will do their best to keep the price down. Since bears are habitual creatures, they are unlikely to seek new prey even if initial data on prescriptions is good. It will take months before bears are thoroughly convinced that non-responder dropout rates are less than replacement rates or less than expected. If they bet wrong, shares will then make up for lost time.
Should we get positive news on both sides of the Atlantic, it may the first convergence of its kind and worth watching, if not participating.